Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients

[1]  G. Sauter,et al.  Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer , 2016, Molecular medicine reports.

[2]  Z. Ye,et al.  Significance of different response evaluation criteria in predicting progression‐free survival of lung cancer with certain imaging characteristics , 2016, Thoracic cancer.

[3]  Ying-Chih Chang,et al.  Circulating Tumor Cell Count Correlates with Colorectal Neoplasm Progression and Is a Prognostic Marker for Distant Metastasis in Non-Metastatic Patients , 2016, Scientific Reports.

[4]  Dapeng Li,et al.  Primary Tumor Resection Is Associated with Improved Survival in Stage IV Colorectal Cancer: An Instrumental Variable Analysis , 2015, Scientific Reports.

[5]  R. Chojniak,et al.  Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer , 2015, Cancer biology & therapy.

[6]  W. El-Deiry,et al.  Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation , 2015, Cancer biology & therapy.

[7]  Chi-Hung Lin,et al.  Dynamic Changes in Numbers and Properties of Circulating Tumor Cells and Their Potential Applications , 2014, Cancers.

[8]  M. Salido,et al.  EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer , 2014, Oncotarget.

[9]  A. Mercurio,et al.  VEGF targets the tumour cell , 2013, Nature Reviews Cancer.

[10]  J. Tabernero,et al.  Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. , 2013, The oncologist.

[11]  S. Dattatreya.  Metastatic colorectal cancer-prolonging overall survival with targeted therapies , 2013, South Asian journal of cancer.

[12]  L. Ellis,et al.  Predictive Biomarkers for Bevacizumab: Are We There Yet? , 2013, Clinical Cancer Research.

[13]  R. Rosell,et al.  Relevance of molecular characterization of circulating tumor cells in breast cancer in the era of targeted therapies , 2013, Expert review of molecular diagnostics.

[14]  S-R Lin,et al.  Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer , 2013, British Journal of Cancer.

[15]  H. Hatabu,et al.  Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. , 2012, AJR. American journal of roentgenology.

[16]  F. Solé,et al.  Biomarkers characterization of circulating tumour cells in breast cancer patients , 2012, Breast Cancer Research.

[17]  S. Chadda,et al.  A systematic review of treatment guidelines for metastatic colorectal cancer , 2012, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[18]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[19]  W. El-Deiry,et al.  Circulating Tumor Cells and Colorectal Cancer , 2010, Current colorectal cancer reports.

[20]  Laura A. Sullivan,et al.  The VEGF family in cancer and antibody-based strategies for their inhibition , 2010, mAbs.

[21]  D. Sargent,et al.  Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144. , 2009, Clinical colorectal cancer.

[22]  C. Kirkpatrick,et al.  Epithelial expression of VEGF receptors in colorectal carcinomas and their relationship to metastatic status. , 2007, Anticancer research.

[23]  D. McDonald,et al.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.

[24]  Napoleone Ferrara,et al.  Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective , 2006, Clinical Cancer Research.

[25]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[26]  L. Poellinger,et al.  Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. , 2003, Carcinogenesis.

[27]  Stephen B Fox,et al.  The angiogenic switch for vascular endothelial growth factor (VEGF)‐A, VEGF‐B, VEGF‐C, and VEGF‐D in the adenoma–carcinoma sequence during colorectal cancer progression , 2003, The Journal of pathology.

[28]  L. Water,et al.  VEGF expression by epithelial and stromal cell compartments: resolving a controversy. , 2000, The American journal of pathology.

[29]  S. Greenland,et al.  Simulation study of confounder-selection strategies. , 1993, American journal of epidemiology.

[30]  Jian Zhao,et al.  Expression of vascular endothelial growth factor in circulating tumor cells for prediction of colorectal cancer , 2017 .

[31]  Jacques Ferlay,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .

[32]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[33]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.